JPMorgan lowered the firm’s price target on Oxford Biomedica to 325 GBp from 495 GBp and keeps a Neutral rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OXBDF:
- Oxford Biomedica, Institut Merieux enter exclusive negotations for ABL Europe
- Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation
- Oxford Biomedica sees 2023 group revenues GBP 90M
- Oxford Biomedica reports 1H EPS (49.74p) vs. (27.29p) last year
- Oxford Biomedica Plc – INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023